| For: | Okamoto T, Koda M, Miyoshi K, Onoyama T, Kishina M, Matono T, Sugihara T, Hosho K, Okano J, Isomoto H, Murawaki Y. Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model. World J Hepatol 2016; 8(22): 933-941 [PMID: 27574547 DOI: 10.4254/wjh.v8.i22.933] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v8/i22/933.htm |
| Number | Citing Articles |
| 1 |
Guillermo A. Ortiz, Guadalupe Garcia-Tsao. Future Pharmacological Therapies of Portal Hypertension. Current Hepatology Reports 2019; 18(1) doi: 10.1007/s11901-019-00448-2
|
| 2 |
Rohan Bhadange, Anil Bhanudas Gaikwad. Modulation of AKT/GSK-3β signaling by ambrisentan alleviates chronic kidney disease. Pathology - Research and Practice 2026; 281 doi: 10.1016/j.prp.2026.156402
|
| 3 |
Henrik H. Hansen, Michael Feigh, Sanne S. Veidal, Kristoffer T. Rigbolt, Niels Vrang, Keld Fosgerau. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today 2017; 22(11) doi: 10.1016/j.drudis.2017.06.007
|
| 4 |
Hunter W. Korsmo. Exploring Endogenous Tryptamines: Overlooked Agents Against Fibrosis in Chronic Disease? A Narrative Review. Livers 2024; 4(4) doi: 10.3390/livers4040043
|
| 5 |
Hongshan Li, Hao Ying, Airong Hu, Yaoren Hu, Dezhou Li. Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis <i>via</i> Regulating Hepatic Lipogenesis and Fatty Acid Oxidation. Biological & Pharmaceutical Bulletin 2017; 40(5) doi: 10.1248/bpb.b16-00942
|
| 6 |
Dina E. Al-Wakeel, Marwa E. Abdelmageed, Mirhan N. Makled, Manar A. Nader. Ambrisentan ameliorates methotrexate-induced pulmonary injury in rats: involvement of ET-1/ETA, NF-κB, and MMP-9/TIMP-1 pathways. Toxicology and Applied Pharmacology 2026; 506 doi: 10.1016/j.taap.2025.117640
|
| 7 |
Calen A. Steiner, Peter D. R. Higgins. Fibrostenotic Inflammatory Bowel Disease. 2018; doi: 10.1007/978-3-319-90578-5_23
|
| 8 |
Francesca Schinzari, Carmine Cardillo. Intricacies of the endothelin system in human obesity: role in the development of complications and potential as a therapeutic target. Canadian Journal of Physiology and Pharmacology 2020; 98(9) doi: 10.1139/cjpp-2019-0651
|
| 9 |
Osvaldo Rivera-Gonzalez, Natalie A. Wilson, Laura E. Coats, Erin B. Taylor, Joshua S. Speed. Endothelin receptor antagonism improves glucose handling, dyslipidemia, and adipose tissue inflammation in obese mice. Clinical Science 2021; 135(14) doi: 10.1042/CS20210549
|
| 10 |
Stefania Cannito, Erica Novo, Maurizio Parola. Therapeutic pro-fibrogenic signaling pathways in fibroblasts. Advanced Drug Delivery Reviews 2017; 121 doi: 10.1016/j.addr.2017.05.017
|
| 11 |
Meng Li, Man Cui, Guoxia Li, Yueqiu Liu, Yunsheng Xu, Seyed Parsa Eftekhar, Moein Ala. The Pathophysiological Associations Between Obesity, NAFLD, and
Atherosclerotic Cardiovascular Diseases. Hormone and Metabolic Research 2024; 56(10) doi: 10.1055/a-2266-1503
|
| 12 |
Jie Wang, Lili An, Yun Zhao, Cheng Zhang, Shengnan Li, Chen Ye, Shuqian Jing, Haiying Hang. In vitro affinity maturation of antibody against membrane-bound GPCR molecules. Applied Microbiology and Biotechnology 2019; 103(18) doi: 10.1007/s00253-019-10030-x
|
| 13 |
Li Feng, Songhua Wang, Feng Chen, Cheng Zhang, Qiao Wang, Yuting Zhao, Zifeng Zhang. Hepatic Knockdown of Endothelin Type A Receptor (ETAR) Ameliorates Hepatic Insulin Resistance and Hyperglycemia Through Suppressing p66Shc-Mediated Mitochondrial Fragmentation in High-Fat Diet-Fed Mice. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; doi: 10.2147/DMSO.S299570
|